杭州九源基因生物医药股份有限公司（九源基因，股票代码：02566）于2026年7月14日发布翌日披露报表，确认在香港联合交易所进行股份回购。
根据公告，九源基因于2026年7月14日合计回购2.4万股H股，占该次回购前已发行股份约0.00999%。每股最高回购价为港币6.1元，最低回购价为港币5.9元，合计付出价格约14.35万港元。回购完成后，九源基因已发行股本增至约2.45亿股（其中计入5,063,800股库藏股），已发行股份（不包括库藏股）则变动至240,335,000股。
公告显示，本次回购基于2026年6月15日通过的购回授权，授权总数为24,151,640股。截至目前，已根据该授权在联交所及其他证券交易所回购1,181,400股，占购回授权通过当日已发行股份（不包括库藏股）总数的约0.48916%。公司同时确认，已遵守香港联交所证券上市规则及相关法律法规的规定。
本次公告由联席公司秘书黄秀签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.